论文部分内容阅读
目的观察吉西他滨联合顺铂治疗晚期乳腺癌的疗效和不良反应。方法对32例晚期乳腺癌患者采用GP方案化疗,采用RECIST标准评价疗效。结果总有效率为40.6%,中位生存期12.7个月。不良反应主要为胃肠道反应和骨髓抑制,无因不良反应终止治疗者,也无化疗相关死亡病例。结论吉西他滨联合顺铂治疗耐蒽环类及紫杉类的晚期乳腺癌疗效较好,不良反应较轻,可作为蒽环类及紫杉类药物治疗失败的晚期乳腺癌的解救方案。
Objective To observe the efficacy and adverse reactions of gemcitabine plus cisplatin in the treatment of advanced breast cancer. Methods Thirty-two patients with advanced breast cancer were treated with GP regimen and the RECIST criteria were used to evaluate the efficacy. The total effective rate was 40.6% and the median survival time was 12.7 months. Adverse reactions were mainly gastrointestinal reactions and bone marrow suppression, no termination of treatment due to adverse reactions, no chemotherapy-related deaths. Conclusion The combination of gemcitabine and cisplatin is effective in the treatment of advanced breast cancer with anthracyclines and taxanes, with less adverse reactions. It can be used as a rescue strategy for patients with advanced breast cancer who have failed to receive anthracyclines and taxanes.